SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Cytovia CEO Daniel Teper/Courtesy Cytovia Therapeu
Drug Development
Cytovia is Empowering NK Cells and NK Engager Antibodies Against Cancer
Cytovia could become the first company to use a combination of natural killer (NK) cells derived from induced pluripotent stem cell (iPSC) and NK engager antibodies to treat solid tumors.
April 11, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
Sutro Delivers Evidence of One-Two Immunogenic Punch at AACR
Sutro Biopharma presented Phase I data at (AACR) showing that its lead compound, STRO-002, not only kills the tumor but also elicits immunogenic cell death.
April 9, 2022
 · 
3 min read
 · 
Gail Dutton
Drug Development
GeoVax’s Novel Vaccine Platform Induces Both Antibody and T Cell Responses
GeoVax is conducting two Phase II COVID-19 vaccine clinical trials with its GEO-CMO4S1 vaccine. One of the trials is among immunocompromised patients.
April 8, 2022
 · 
5 min read
 · 
Gail Dutton
Michael Vi/Getty Images, Mark Wildgust_Janssen Bio
Drug Development
At AAN, Janssen Shows IgG Levels are Effective Biomarker for Generalized Myasthenia Gravis Treatments
Janssen’s Phase II study of nipocalimab for generalized myasthenia gravis (gMG) shows that serum IgG levels can be used as a supportive biomarker to manage this disease.
April 7, 2022
 · 
4 min read
 · 
Gail Dutton
Genetown
The Future of Gene Editing Takes a Toolbox that Extends Beyond Cas9
Carver Biosciences is developing next-generation gene editing technology using Cas13. By editing RNA, this method makes it possible to target and then edit or destroy RNA from viruses like SARS-CoV-2.
April 6, 2022
 · 
3 min read
 · 
Gail Dutton
Drug Development
New Therapies Bring Meaningful Life Extension to Pancreatic Cancer Patients
Speakers at the 2022 Virtual Growth Conference’s session on pancreatic cancer acknowledged the exceptional challenges while extolling advances in immune-based therapies and combination approaches.
April 5, 2022
 · 
4 min read
 · 
Gail Dutton
Rep. Frank Pallone, Jr. (D-NJ)/Voice of America
FDA
Accelerated Approval Integrity Act Could Remove Therapies Before They Prove Merit
The Accelerated Approval Integrity Act of 2022 (H.R. 6963) aims to remove loopholes in the FDA’s accelerated approval pathway. The bill, however, fails to adequately consider the whole picture.
April 4, 2022
 · 
5 min read
 · 
Gail Dutton
2023 Will Be Pivotal Year for Oculis’ Potentially Transformative Medicines
Oculis has identified pressing unmet therapeutic needs and innovative, differentiated approaches to meet those needs.
April 3, 2022
 · 
4 min read
 · 
Gail Dutton
Drug Development
Origami Brings Protein Degradation to Neurodegenerative Disorders
Origami’s precision technology platform, Oricision™, is focused on diseases that affect the central nervous system rather than oncology.
March 31, 2022
 · 
4 min read
 · 
Gail Dutton
CODA CSO Susan Catalano/Courtesy CODA Biotherapeut
Business
Pursuit of Scientific Challenges Drives New CODA CSO Susan Catalano
Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.
March 30, 2022
 · 
5 min read
 · 
Gail Dutton
Photo courtesy of Sana Biotechnology
BioForest
Sana On Track to Remove Barriers for Cell & Gene Therapy
Before cell and gene therapy can truly become mainstream medicine, the challenges of allogeneic rejection and targeted delivery must be solved. Sana Biotechnology is on the path to do that.
March 28, 2022
 · 
6 min read
 · 
Gail Dutton
Business
Rick Bright, Others Offer Advice for Holding Back Another COVID-19 Surge
COVID-19 cases are soaring in China, Hong Kong, the U.K. and parts of Europe. A recent Demy-Colton Virtual Salon explored what we can expect in the near future.
March 27, 2022
 · 
5 min read
 · 
Gail Dutton
Cure Innovation Labs_Courtesy of The Deerfield Fou
Business
NYC’s Cure Innovation Labs Bridges the Gap for Pre-Series A Biotechs
Mark Veich, president of Advancium Health Network and executive director of the Deerfield Foundation, characterized Cure Innovation Labs as an ‘excel-erator.’
March 26, 2022
 · 
4 min read
 · 
Gail Dutton
The Small Pharma team who is developing new approa
Drug Development
DMT-Assisted Therapy May Address Root Cause of Major Depressive Disorder
Small Pharma Inc. is developing a new approach to treat major depressive disorder (MDD) without using SSRIs or standard medications. Here’s what they are using.
March 25, 2022
 · 
5 min read
 · 
Gail Dutton
Automation in pharmaceutical industry has increase
Policy
Automation in Pharmaceutical Industry Makes it a Prime Target for Cyber Attacks: Be Ready
Automation in pharmaceutical industry can make the companies target of the cyber threats emanating from Russia, China, and North Korea. It can be collateral or direct.
March 24, 2022
 · 
5 min read
 · 
Gail Dutton
Load More